Sun Pharma gains on inking pact with Lundbeck to market, distribute Vortioxetine in India
Follow us Now on Telegram ! Get daily 10 - 12 important updates on Business, Finance and Investment. Join our Telegram Channel
https://t.me/InvestmentGuruIndiacom
Download Telegram App before Joining the Channel
Sun Pharmaceutical Industries is currently trading at Rs. 920.05, up by 0.55 points or 0.06% from its previous closing of Rs. 919.50 on the BSE.
The scrip opened at Rs. 920.00 and has touched a high and low of Rs. 921.95 and Rs. 908.30 respectively. So far 66897 shares were traded on the counter.
The BSE group 'A' stock of face value Rs. 1 has touched a 52 week high of Rs. 930.90 on 21-Mar-2022 and a 52 week low of Rs. 587.50 on 30-Mar-2021.
Last one week high and low of the scrip stood at Rs. 921.95 and Rs. 885.55 respectively. The current market cap of the company is Rs. 220606.85 crore.
The promoters holding in the company stood at 54.48%, while Institutions and Non-Institutions held 33.99% and 11.53% respectively.
Sun Pharmaceutical Industries has entered into an exclusive patent licensing agreement with H. Lundbeck A/S (Lundbeck) to market and distribute its own version of Vortioxetine in India under the brand name, ‘Vortidif’. The territory of the licensing agreement will only cover India.
Vortioxetine is a novel antidepressant with multimodal activity, which is approved to treat Major Depressive Disorder (MDD) in adults. The product is approved in over 80 countries, including the US, EU, Canada and Australia.
Sun Pharmaceutical Industries is the world's fourth largest specialty generic pharmaceutical company and India's top pharmaceutical company.
